Work

News Beyond Our Pages

Year: 2020

Type: article

Abstract: Despite our increasing understanding of the pathogenesis of aspirin-exacerbated respiratory disease, including excess cysteinyl leukotriene production and mast-cell activation, treatment options remain limited. Hayashi et al (Am J Respir Crit Care Med. 2020 Mar 6. https://doi.org/10.1164/rccm.201906-1215OC) performed the first double-blind, randomized controlled trial examining the efficacy of the anti-IgE mAb omalizumab in patients with aspirin-exacerbated respiratory disease and detectable environmental allergen-specific IgE.

Source: Journal of Allergy and Clinical Immunology

DOI: 10.1016/j.jaci.2020.04.020

Authors: Marc E. Rothenberg, Jean Bousquet

Language: English

Topic: Asthma and respiratory diseases

Subfield: Physiology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,550

OpenAlex ID: W4206841360

FWCI:

Cites:

Cited by:

Related to: 10